contact us

Use the form on the right to contact us.

You can edit the text in this area, and change where the contact form on the right submits to, by entering edit mode using the modes on the bottom right.

         

123 Street Avenue, City Town, 99999

(123) 555-6789

email@address.com

 

You can set your address, phone number, email and site description in the settings tab.
Link to read me page with more information.

ardenHEADER.jpg

Arden's Day Blog

Arden's Day is a type I diabetes care giver blog written by author Scott Benner. Scott has been a stay-at-home dad since 2000, he is the author of the award winning parenting memoir, 'Life Is Short, Laundry Is Eternal'. Arden's Day is an honest and transparent look at life with diabetes - since 2007.

type I diabetes, parent of type I child, diabetes Blog, OmniPod, DexCom, insulin pump, CGM, continuous glucose monitor, Arden, Arden's Day, Scott Benner, JDRF, diabetes, juvenile diabetes, daddy blog, blog, stay at home parent, DOC, twitter, Facebook, @ardensday, 504 plan, Life Is Short, Laundry Is Eternal, Dexcom SHARE, 生命是短暂的,洗衣是永恒的, Shēngmìng shì duǎnzàn de, xǐyī shì yǒnghéng de

Filtering by Category: Daddy's Blog

Sanofi Insulin Pricing Program

Scott Benner

from press release - 4/10/19

Starting in June, Sanofi will further expand its innovative Insulins Valyou Savings Program so people living with diabetes in the United States can pay $99 to access their Sanofi insulins* with a valid prescription, for up to 10 boxes of pens and/or 10 mL vials per month. The expansion of this program helps to address the challenge too many patients face regarding unpredictable and unaffordable pricing for their insulin. 

People living with diabetes in the United States can pay $99 to access their Sanofi insulins* with a valid prescription, for up to 10 boxes of pens and/or 10 mL vials per month.

People exposed to high out-of-pocket prices at the pharmacy counter can participate in the Insulins Valyou Savings Program regardless of income level. This includes those who are paying high retail prices for their insulin and those who don't qualify for other patient assistance programs. 

Under current government regulations, pharmaceutical companies cannot offer this type of program to patients insured under Medicare, Medicaid, or similar federal or state programs, though Sanofi supports changing rules to expand this access program to all those who might benefit.

For more information or to learn how to access this program, visit www.InsulinsValYOU.com.

Additional patient resources available for accessing Sanofi medicines

Sanofi continues to offer other resources to make insulins more accessible including co-pay cards which may limit out-of-pocket expenses sometimes to $0 for all commercially insured patients regardless of income level. In addition, Sanofi offers assistance programs that provide medications, including insulin, at no charge for qualified low-income, uninsured patients through the patient assistance component of the Sanofi Patient Connection program. Together, these programs demonstrate the company's dedication to finding support to help people living with diabetes gain access to the insulins they need.

Sanofi also encourages anyone who is prescribed a Sanofi medicine who may be having financial challenges or trouble navigating their insurance, to call Sanofi Patient Connection at (888) 847-4877 where eligible patients can be connected to the medicines and resources they need at no cost.

* The Insulins Valyou Savings Program does not include Sanofi's combination insulin product.


The entire press release is available
here








An Average Day with Type 1 Diabetes

Scott Benner

Most days are perfectly imperfect…

If you already listen to the Juicebox Podcast this quick post will serve as a reminder that:

  • There is a way to eat normally and achieve the A1c that you want.

  • A great A1c doesn’t necessarily mean that your BG is 85 (4.7) all day and night long.

  • Just because you haven’t figured something out doesn't mean that an answer doesn’t exist.

If you haven’t yet listened, I hope that this post represents what is possible when you:

  • Have easy to understand tools for using insulin.

Listen to the Juicebox Podcast at  JuiceboxPodcast.com ,  Apple Podcasts ,  Spotify  or on your favorite podcast app..

Listen to the Juicebox Podcast at JuiceboxPodcast.com, Apple Podcasts, Spotify or on your favorite podcast app..

Try these episode to start #11 Bold With insulin, #29 Fear of insulin, #37, Jenny Smith, #44 Diabetes Rollercoaster, #62 Unfounded Fear, #100 Revisiting Bold, #105 All About A1c, #121 Insulin, Insulin, Insulin

You can always listen to the Juicebox Podcast or your favorite podcast app but if you don’t have one try one of these.  Apple Podcasts/iOS - Spotify - Amazon Alexagoogle play/android - iheart radio -  .


Insulin Assistance Programs - Programas de Asistencia con Insulina

Scott Benner

We are grateful to be insured and to have access to affordable insulin.

If you are uninsured, underinsured or struggling to pay for insulin... there are programs that can help.

Desplácese hacia abajo para la traducción al español

from Eli Lilly - If you have no insurance, are underuninsured or affected by the Government shutdown and would like more facts about Lilly’s patient assistance programs.

There are live representatives at the Lilly Diabetes Solution Center to help people find cost saving solutions for their Lilly insulins based on individual circumstances – including government employees. Call the Solution Center at 833-808-1234 Monday through Friday from 8 a.m. to 9 p.m. EST. or visit their website.

from Novo Nordisk - The Novo Nordisk Patient Assistance Program (PAP) is our continued commitment to people living with diabetes and the Novo Nordisk Triple Bottom Line. The Diabetes PAP provides free medicine to those who qualify. If approved, a free 120-day supply of medicine will be sent to the prescribing health care providers’ office to be picked up at the patient's convenience. Novo Nordisk will automatically contact the health care provider prior to your next refill to approve the medication reorder. More info on their website.

from Sanofi - Our passion is to improve access to medicines and healthcare. Patients are our number one priority, and to meet their needs more efficiently, Sanofi US offers an integrated patient support program titled Sanofi Patient Connection (SPC). More info on their website. 

If you have more or different links please contact me and I will add them to this list. Thank you!


"Because of your podcast (Juicebox), I have significantly reduced the amount of spikes that I get."

Estamos agradecidos de estar asegurados y de tener acceso a una insulina asequible.

Si no tiene seguro, tiene un seguro insuficiente o tiene dificultades para pagar la insulina ... existen programas que pueden ayudarlo.

de Eli Lilly: Si no tiene seguro, no tiene seguro o está afectado por el cierre del gobierno y le gustaría obtener más información sobre los programas de asistencia al paciente de Lilly.

Hay representantes en vivo en el Centro de Soluciones para la Diabetes de Lilly para ayudar a las personas a encontrar soluciones económicas para sus insulinas de Lilly según las circunstancias individuales, incluidos los empleados del gobierno. Llame al Centro de soluciones al 833-808-1234 de lunes a viernes de 8 a.m. a 9 p.m. EST. o visite su sitio web.

de Novo Nordisk: El Programa de Asistencia al Paciente (PAP) de Novo Nordisk es nuestro compromiso continuo con las personas que viven con diabetes y la Línea de Triple Beneficio de Novo Nordisk. El Diabetes PAP proporciona medicamentos gratuitos a quienes califican. Si se aprueba, se enviará un suministro gratuito de 120 días de medicamentos al consultorio de los proveedores de atención médica que prescriben para que lo recojan a la conveniencia del paciente. Novo Nordisk se comunicará automáticamente con el proveedor de atención médica antes de su próxima renovación para aprobar el nuevo pedido de medicamentos. Más información en su página web.

de Sanofi: Nuestra pasión es mejorar el acceso a los medicamentos y la atención médica. Los pacientes son nuestra prioridad número uno, y para satisfacer sus necesidades de manera más eficiente, Sanofi US ofrece un programa integrado de asistencia al paciente titulado Sanofi Patient Connection (SPC). Más información en su página web.

Si tiene más o diferentes enlaces, por favor contácteme y los agregaré a esta lista. ¡Gracias!

On This day, January 11 1922: Insulin Was First Used to Treat Diabetes

Scott Benner

On Jan. 11, 1922 fourteen-year-old Leonard Thompson was injected with a pancreatic extract prepared by Dr. Frederick Banting, and medical student, Charles Best.

from TheStar.com:

Although his blood sugars went down a little, there was not a lot of change following Thompson’s initial injection, according to the University of Toronto’s heritage website.

But biochemist Bert Collip, who had been working with Banting and Best in a lab provided by the university’s head physiologist, Prof. J.J.R.. Macleod, developed a method to refine the extract and daily injections of this extract started Jan. 23. Improvement was immediate and remarkable. The boy’s blood sugar levels dropped to normal levels (Thompson would live another 13 years with daily injections of insulin, before dying of tuberculosis.)

It was not a cure but it was a monumental breakthrough in treatment for what had been an untreatable disease.

In March, 1922 a paper describing the case of Leonard Thompson, and six other patients the Banting and Best team treated with the refined extract, was published in the Canadian Medical Association Journal. It was the first official announcement of an extract developed to alleviate the symptoms of diabetes.

A message of hope to sufferers from diabetes goes out authentically today from the medical research laboratories of the University of Toronto. The modesty of medical men and scientific investigators of the genuine brand attempts to minimize the results obtained. The harm of exaggeration and the injustice to both parents and research men in awakening false and premature hopes before the extracts can possibly be manufactured cannot be over-emphasized. But the fact remains that one of the most important discoveries in modern medical research has been made at the university here. It is not a cure for diabetes, its authors state. Within six months, however, their discovery will be used on a large scale, they hope, to prolong life quite considerably at least. There will be no secrecy, as from the beginning. The medical profession will know all the facts.
— The Toronto Daily Star - March 22, 1922 Edition

The Toronto Daily Star broke the news a day before other outlets. The March 22, 1922 bold all-capital headline ran eight columns on the front page: “Toronto doctors on track of diabetes cure.” A subhead stated: “Discovery made at University of Toronto will be means of prolonging life considerably — F.G. Banting and C.H. Best pushed experiments all last summer.”

The Star referred to the Alliston-born Banting — who had won the Military Cross in 1916 for bravery in World War I — as being “strangely slow in speech” and “unassuming” but he also had “the reputation of coming across with the punch at the critical moment.”

click to enlarge

Two months later, on May 22, 1922, Prof. Macleod delivered a paper on the U of T team’s findings to the American Association of Medical Physicists in Washington, D.C. and got a standing ovation. Macleod used the term “insulin” to describe the extract. According to the Canadian Encyclopedia, “in the eyes of most of the world,” this was considered the announcement of insulin.

The next year, on Oct. 26, 1923, the first Nobel prize awarded to Canadians was given to Banting and Macleod.

But the reaction of Banting and Macleod to the prize revealed a little of the testy relationship that had existed in the background between the two men.

According to an account on the website scienceheroes.com (similar to other published reports) Banting was furious that he was sharing the award with Macleod, not Best, and at first swore he “wouldn’t accept the award.” But friends persuaded him that it wouldn’t be smart to refuse the first Nobel for a Canadian (he remains the youngest Nobel Laureate in Physiology/Medicine). Instead, Banting announced he would split his share of the $40,000 monetary prize with Best.

read the story in it’s entirety at TheStar.com


Statement from FDA Commissioner on Insulin Pricing

Scott Benner

The FDA has issued a statement intended to spur competition and lower prices. I’ve pulled out and included a few passages that are about insulin. You can read the entire statement as written here.

from FDA.gov

Statement from FDA Commissioner Scott Gottlieb, M.D., on new actions advancing the agency’s biosimilars policy framework.

There are currently no approved insulin products that can be substituted at the pharmacy level. One reason is that it was hard to bring a substitutable generic insulin to the market under the conventional drug pathway. The biosimilar pathway should make this kind of competition more accessible. Once an interchangeable insulin product is approved and available on the market, it can then be substituted for the reference product at the pharmacy, potentially leading to increased access and significantly lower costs for patients.

We’re going to be monitoring these markets. And we’ll be taking additional actions. We’re actively evaluating how we can make it easier for biosimilar manufacturers to use reference products from outside the U.S., where prices may be cheaper and reference products more accessible.

We’re also releasing today two critical guidance documents that describe how the agency plans to implement Congress’ direction that we transition certain biological products currently approved as drugs under the FD&C Act to be licensed as biologics under the PHSA.

Transitioning these drugs to the PHSA will let them to be treated as biologics under that law. And that means opening them up to competition through the biosimilars pathway. This includes insulin, which has been historically regulated as a drug and not a biologic.

Starting in March 2020, the approved marketing applications for the small subset of “biological products” such as insulin and human growth hormone – which for complex historical reasons were previously generally approved as drugs under section 505 of the FD&C Act – will be deemed to be biologics licenses under section 351 of the PHSA. Sponsors have known about this transition for a decade. They’ve had time to prepare.

As a result, we’ve heard frequent reports of patients rationing insulin, and in some cases dying because they can’t afford the injections they need to survive. These tragic stories aren’t isolated occurrences. And they’re not acceptable for a drug that’s nearly a century old.

Today, we’re laying out our policy on how these products will transition from the drug pathway to the biologics pathway, and in so doing, how we intend to use this new framework to promote competition. The two guidance documents we’re releasing today, one final and one draft, describe how the FDA intends to accomplish the transition of these products under the “Deemed to be a License” provision of the BPCI Act. The final guidance deals with “Interpretation of the ‘Deemed to be a License’ Provision of the Biologics Price Competition and Innovation Act of 2009,” finalizes the FDA’s draft guidance from 2016.

We’ve shaped these policies to implement the intent of Congress, and to make sure a few things happen. First, that the anti-evergreening provisions under the biosimilars legislation – meant to prevent sponsors from being able to game the exclusivity provisions to forestall biosimilar entry – will apply to these newly deemed products, including insulin.